Ryan Conrad

In the final part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he discusses how FDA’s new program may or may not impact manufacturing pipelines.

In the first part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he provides a broad overview of the possible positive and negative impacts of FDA’s Priority Review Voucher Program.